Clarivate

驱动战略领域创新，为合作决策奠定基础

生命科学公司正在寻求最有效的交易策略，以创造合理价值并在关键领域拓展产品组合深度。从剥离与战略重点不符的资源，到合作“试水”人工智能（AI）和机器学习（ML）等可能颠覆行业的机遇，大型制药公司都愿意为合适的平台或资产豪掷千金，但在投资决策方面仍保持高度谨慎。

invoX Pharma（中国生物制药子公司）旗下公司 F-star Therapeutics Inc 与武田制药达成第三项肿瘤学领域的许可协议，该协议潜在价值高达 10 亿美元。

大型制药公司优先研发的治疗领域

完整填写下方表单
免费下载中文报告完整版

姓*

名*

工作邮箱*

公司（机构）名称（英文）*

公司（机构）名称（中文）*

公司（机构）类型*

工作职能*

职位*

手机*

省份*

国家/地区*

我们该如何帮助您？

欢迎通过邮件订阅科睿唯安专业资讯。您可以随时取消订阅。

HIDDEN FIELDS BELOW

SBU of Lead

Primary Product

Sub Primary Products

PQ Specialist Type

Lead Source - Most Recent

Last Follow Up

Lead Routing

Lead Status

Marketing Lead Status

address1

“Due to the ease of access and the variety of content and formats available, ExLibris will enable our academic community to access information that produces better outcomes.”

Tomomi Asano, Manager of the Public Service Group at International Christian University Library

“Due to the ease of access and the variety of content and formats available, ExLibris will enable our academic community to access information that produces better outcomes.”

Tomomi Asano, Manager of the Public Service Group at International Christian University Library

“Due to the ease of access and the variety of content and formats available, ExLibris will enable our academic community to access information that produces better outcomes.”

Tomomi Asano, Manager of the Public Service Group at International Christian University Library